# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
MB Number:	3235-0287				
stimated average					
ours per response 0.5					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting Per Fishman Corey N.	2. Issuer Name and Ticker or Trading Symbol Iterum Therapeutics plc [ITRM]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) C/O ITERUM THERAPEUTICS 3, HARCOURT CENTRE, HAR	3. Date of Earliest Transaction (Month/Day/Year) 05/30/2018						X Officer (give title below) Other (specify below) President & CEO			
(Street) DUBLIN, L2 2	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)X_Form filed by One Reporting PersonForm filed by More than One Reporting Person			
(City) (State)	(Zip)	Ta	ble I - Non-	-Deri	vative Se	curities	Acqu	ired, Disposed of, or Beneficially (	Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		4. Securi (A) or D (D) (Instr. 3,	4 and 5 (A) or	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
Ordinary Shares	05/30/2018		С		33,259	A	<u>(1)</u>	229,312	D	
Ordinary Shares	05/30/2018		С		4,050	A	<u>(2)</u>	233,362	D	
Ordinary Shares	05/30/2018		С		1,591	A	<u>(3)</u>	234,953	D	
Ordinary Shares	05/30/2018		P		3,000	A	\$ 13	237,953	D	
Reminder: Report on a separate line fo	r each class of securition	es beneficially owne			•	L	nd to	the collection of information	SEC	1474 (0.02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

Deemed 4. 5. Number 6. Date Exercisable 7. Title and

contained in this form are not required to respond unless the form displays a currently valid OMB control number.

			(6.8	., puis, c	ans	mai	i ants, o	puons, conv	ci tibic secu	iritics					
1. Title of				4.				6. Date Exer		7. Title and					11. Nature
Security	Conversion or Exercise Price of Derivative Security	(Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Code		Der Sect Acq (A) Disp (D)	ivative urities uired or posed of tr. 3, 4,	and Expirati (Month/Day	//Year)	Amount of Underlying Securities (Instr. 3 an	,	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Derivative Security: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Shares	<u>(1)</u>	05/30/2018		С			33,259	<u>(1)</u>	<u>(4)</u>	Ordinary Shares	33,259	\$ 0	0	D	
Series B- 1 Preferred Shares	<u>(2)</u>	05/30/2018		С			4,050	(2)	<u>(4)</u>	Ordinary Shares	4,050	\$ 0	0	D	
Series B- 2 Preferred Shares	(3)	05/30/2018		С			1,591	<u>(3)</u>	<u>(4)</u>	Ordinary Shares	1,591	\$ 0	0	D	

### **Reporting Owners**

B (C N /AII	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
Fishman Corey N. C/O ITERUM THERAPEUTICS PLC, BLK 2 FL. 3, HARCOURT CENTRE, HARCOURT ST. DUBLIN, L2 2	X		President & CEO			

### **Signatures**

/s/ Corey N. Fishman	05/30/2018

**Signature of Reporting Person	D	ate

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- (2) The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- (3) The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.
- (4) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.